United Health Products, INC

United Health Products, Inc. has entered into an agreement with NAMSA to serve as the regulatory sponsor for a new clinical study of its CelluSTAT Hemostatic Gauze, a key step in its FDA Premarket Approval application process.

United Health Products, Inc. has secured a $289,821 senior convertible promissory note and established a $4 million equity line with Alumni Capital LP to bolster its financial position and fund general corporate purposes.

United Health Products, Inc. announced the resignation of Kristofer Heaton as Vice President of Finance and Principal Financial Officer, with CEO Brian Thom stepping in as interim Principal Financial Officer.

United Health Products announces its common shares have been uplisted to the OTCQB Venture Market and provides an update on its FDA application for CelluSTAT Hemostatic Gauze.

United Health Products announced an update on its FDA Premarket Approval application for its HemoStyp gauze, including the need for additional clinical data.

United Health Products has further amended its Common Stock Purchase Agreement with White Lion Capital, modifying the purchase price calculation for shares.

United Health Products reports zero revenue for Q1 2026 as it continues to focus on FDA Premarket Approval for its CelluSTAT hemostatic gauze.

United Health Products, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, alongside ongoing FDA regulatory challenges for its CelluSTAT product and a 'going concern' warning.

United Health Products, Inc. reported continued net losses and significant regulatory challenges for its CelluSTAT hemostatic gauze, including an FDA Warning Letter and disapproval of a key clinical trial application.

United Health Products reports no revenue for Q1 2025 as it continues to pursue FDA Premarket Approval for its CelluSTAT hemostatic gauze.

United Health Products reports a net loss for Q3 2024, with no revenue, as the company continues to focus on obtaining FDA approval for its CelluSTAT product.

United Health Products reported a net loss for the second quarter of 2024 and is addressing deficiencies in its FDA application for its hemostatic gauze product.

United Health Products reports continued operating losses and significant regulatory hurdles as it seeks FDA approval for its CelluSTAT hemostatic gauze.

United Health Products' 2024 10-K filing reveals ongoing efforts to secure FDA approval for its CelluSTAT hemostatic gauze while navigating financial challenges and operational adjustments.

United Health Products reports its 2023 financial results and provides an update on its FDA application for its hemostatic gauze product.

Brian David Thom, CEO of United Health Products, Inc., purchased 32,000 common shares at $0.24 per share on April 8, 2025.

Brian Thom, CEO of United Health Products, Inc., purchased 18,000 shares of the company's common stock at $0.26 per share on March 31, 2025.

United Health Products, Inc. is navigating significant FDA regulatory challenges for its CelluSTAT hemostatic gauze while securing up to $4 million in new financing from Alumni Capital LP.

United Health Products, Inc. files an amendment to its S-1 registration statement to include a new exhibit related to accounting firm consent.

United Health Products seeks to register 15 million shares for resale by White Lion Capital as it awaits FDA decision on its hemostatic gauze product.

United Health Products registers 15 million shares for resale by White Lion Capital under existing purchase agreement.

United Health Products seeks to register the resale of 15 million common shares by White Lion Capital, aiming to fulfill obligations under their Common Stock Purchase Agreement.